RESUMO
Hypertension is the most significant modifiable risk factor for cerebrovascular disease. It has been estimated that about 54% of strokes worldwide can be attributed to hypertension. However, there has not been a systematic study assessing the shared genetic susceptibility to hypertension and stroke on a genome-wide level. In this study, SNPs associated with essential hypertension and stroke were collected from the NHGRI-EBI GWAS catalog, and genotype imputation were conducted using information from the 1000 Genomes Project. Subsequently, the SNPs and the mapped genes were compared between the two diseases. Finally, functional clustering was performed, and the enriched GO terms and KEGG pathways were further compared between hypertension and stroke. Comparison of these two groups of SNPs and genes identified only one shared SNP (rs3184504) and 11 shared genes. After genotype imputation, 129 shared SNPs and 16 shared genes were identified. These genes were significantly enriched in 10 GO terms, which were mainly involved in lipoprotein and triglyceride metabolism. Additionally, KEGG analysis identified one pathway, glycerolipid metabolism, as being significantly enriched in both diseases. The present study strongly suggests that the gene network regulating lipid metabolism and blood circulation is the major shared genetic etiology of hypertension and stroke.
Assuntos
Hipertensão/genética , Acidente Vascular Cerebral/genética , Estudo de Associação Genômica Ampla , Humanos , Polimorfismo de Nucleotídeo ÚnicoRESUMO
In candidate gene era, dozens of single-nucleotide polymorphisms (SNPs) within renin-angiotensin-aldosterone system (RAAS) have been reported to be significantly associated with hypertension. However, the unbiased genome-wide association studies (GWAS) rarely identified the SNPs within RAAS were associated with hypertension or blood pressure (BP) traits. In order to figure out whether genetic polymorphisms of RAAS are really associated with hypertension, we systemically searched the GWAS Catalogue and identified all the known RAAS genes and relevant diseases/traits. After data processing, we found that polymorphisms within REN, AGT, ACE2, CYP11B2, ATP6AP2 and HSD11B2 were not associated with any disease or trait. SNPs within ACE, AGTR1, AGTR2, MAS1, RENBP and NR3C2 were associated with other diseases or traits, but showed no direct connection with hypertension. The only SNP associated with a BP trait, systolic BP was rs17367504. However, it is located in the intronic region of MTHFR near many plausible candidate genes, including CLCN6, NPPA, NPPB and AGTRAP. Therefore, the effect of RAAS polymorphisms may have been overestimated during the 'candidate gene era'. In the time of 'precision medicine', the power of RAAS variants needs to be reconsidered when evaluating one's susceptibility of hypertension.
Assuntos
Pressão Sanguínea/genética , Hipertensão Essencial/genética , Polimorfismo de Nucleotídeo Único , Sistema Renina-Angiotensina/genética , Hipertensão Essencial/diagnóstico , Hipertensão Essencial/fisiopatologia , Predisposição Genética para Doença , Estudo de Associação Genômica Ampla , Humanos , Fenótipo , Proto-Oncogene Mas , Fatores de RiscoRESUMO
BACKGROUND AND PURPOSE: The histamine H4 receptor is widely expressed in cells of immune origin and has been shown to play a role in a variety of inflammatory processes mediated by histamine. In this report, we describe the in vitro and in vivo anti-inflammatory properties of a potent histamine H4 receptor antagonist, A-940894 (4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-ylamine). EXPERIMENTAL APPROACH: We have analysed the pharmacological profile of A-940894 at mouse native, rat recombinant and human recombinant and native, histamine H4 receptors by radioligand binding, calcium mobilization, mast cell shape change, eosinophil chemotaxis assays and in the mouse model of zymosan-induced peritonitis. KEY RESULTS: A-940894 potently binds to both human and rat histamine H4 receptors and exhibits considerably lower affinity for the human histamine H1, H2 or H3 receptors. It potently blocked histamine-evoked calcium mobilization in the fluorometric imaging plate reader assays and inhibited histamine-induced shape change of mouse bone marrow-derived mast cells and chemotaxis of human eosinophils in vitro. In a mouse mast cell-dependent model of zymosan-induced peritonitis, A-940894 significantly blocked neutrophil influx and reduced intraperitoneal prostaglandin D2 levels. Finally, A-940894 has good pharmacokinetic properties, including half-life and oral bioavailability in rats and mice. CONCLUSIONS AND IMPLICATIONS: These data suggest that A-940894 is a potent and selective histamine H4 receptor antagonist with pharmacokinetic properties suitable for long-term in vivo testing and could serve as a useful tool for the further characterization of histamine H4 receptor pharmacology.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Piperazinas/farmacologia , Pirimidinas/farmacologia , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Animais , Anti-Inflamatórios não Esteroides/farmacocinética , Ligação Competitiva , Cálcio/metabolismo , Forma Celular , Quimiotaxia , Eosinófilos/efeitos dos fármacos , Eosinófilos/fisiologia , Feminino , Histamina/farmacologia , Humanos , Masculino , Mastócitos/citologia , Mastócitos/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos BALB C , Peritonite/induzido quimicamente , Peritonite/tratamento farmacológico , Peritonite/imunologia , Piperazinas/farmacocinética , Prostaglandina D2/metabolismo , Pirimidinas/farmacocinética , RNA Mensageiro/biossíntese , Ensaio Radioligante , Ratos , Ratos Sprague-Dawley , Receptores Acoplados a Proteínas G/biossíntese , Receptores Acoplados a Proteínas G/genética , Receptores Histamínicos/biossíntese , Receptores Histamínicos/genética , Receptores Histamínicos H4 , Proteínas Recombinantes/antagonistas & inibidores , ZimosanRESUMO
BACKGROUND AND PURPOSE: Activation of cannabinoid (CB) receptors decreases nociceptive transmission in inflammatory or neuropathic pain states. However, the effects of CB receptor agonists in post-operative pain remain to be investigated. Here, we characterized the anti-allodynic effects of WIN 55,212-2 (WIN) in a rat model of post-operative pain. EXPERIMENTAL APPROACH: WIN 55,212-2 was characterized in radioligand binding and in vitro functional assays at rat and human CB(1) and CB(2) receptors. Analgesic activity and site(s) of action of WIN were assessed in the skin incision-induced post-operative pain model in rats; receptor specificity was investigated using selective CB(1) and CB(2) receptor antagonists. KEY RESULTS: WIN 55,212-2 exhibited non-selective affinity and agonist efficacy at human and rat CB(1) versus CB(2) receptors. Systemic administration of WIN decreased injury-induced mechanical allodynia and these effects were reversed by pretreatment with a CB(1) receptor antagonist, but not with a CB(2) receptor antagonist, given by systemic, intrathecal and supraspinal routes. In addition, peripheral administration of both CB(1) and CB(2) antagonists blocked systemic WIN-induced analgesic activity. CONCLUSIONS AND IMPLICATIONS: Both CB(1) and CB(2) receptors were involved in the peripheral anti-allodynic effect of systemic WIN in a pre-clinical model of post-operative pain. In contrast, the centrally mediated anti-allodynic activity of systemic WIN is mostly due to the activation of CB(1) but not CB(2) receptors at both the spinal cord and brain levels. However, the increased potency of WIN following i.c.v. administration suggests that its main site of action is at CB(1) receptors in the brain.
Assuntos
Analgésicos/farmacologia , Benzoxazinas/farmacologia , Córtex Cerebral/efeitos dos fármacos , Modelos Animais de Doenças , Morfolinas/farmacologia , Naftalenos/farmacologia , Dor Pós-Operatória/tratamento farmacológico , Receptor CB2 de Canabinoide/agonistas , Analgésicos/administração & dosagem , Animais , Benzoxazinas/administração & dosagem , Linhagem Celular , Córtex Cerebral/metabolismo , Pé/patologia , Humanos , Injeções Intraperitoneais , Masculino , Morfolinas/administração & dosagem , Naftalenos/administração & dosagem , Ratos , Ratos Sprague-Dawley , Receptor CB2 de Canabinoide/antagonistas & inibidores , Medula Espinal/efeitos dos fármacosRESUMO
We investigated the systemic and site-specific actions of a selective CB(2) receptor agonist, A-836339 on mechanically evoked (10 g von Frey hair) and spontaneous firing of spinal wide dynamic range (WDR) neurons in neuropathic (L5 and L6 ligations) and sham rats. Systemic administration of A-836339 (0.3-3 micromol/kg, i.v.) reduced both evoked and spontaneous WDR neuronal activity in neuropathic, but not sham rats. The effects in neuropathic rats were blocked by pre-administration of a CB(2), but not a CB(1), receptor antagonist. Similar to systemic delivery, intra-spinal injection of A-836339 (0.3 and 1 nmol) also attenuated both von Frey-evoked and spontaneous firing of WDR neurons in neuropathic rats. Intra-spinal injections of A-836339 were ineffective in sham rats. Application of A-836339 (3-30 nmol) onto the ipsilateral L5 dorsal root ganglion (DRG) of neuropathic rats reduced the von Frey-evoked activity of WDR neurons, but spontaneous firing was unaltered. All effects of A-836339 on WDR neuronal activity following either intra-spinal or intra-DRG administration were blocked by pre-administration of a CB(2) receptor antagonist. Pre-administration of a CB(1) receptor antagonist did not alter the site-specific effects of A-836339. Injection of A-836339 (300 nmol) into the neuronal receptive field on the ipsilateral hind paw did not affect evoked or spontaneous firing of WDR neurons. Thus, the current data demonstrate that modulation of spinal neuronal activity by a CB(2) receptor agonist is enhanced following peripheral nerve injury, and further delineate the contribution of spinal and peripheral CB(2) receptors to this modulation.
Assuntos
Potenciais de Ação/efeitos dos fármacos , Gânglios Espinais/patologia , Neurônios/efeitos dos fármacos , Doenças do Sistema Nervoso Periférico/patologia , Receptor CB2 de Canabinoide/agonistas , Medula Espinal/patologia , Animais , Canfanos/farmacologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Vias de Administração de Medicamentos , Masculino , Estimulação Física/métodos , Piperidinas/farmacologia , Pirazóis/farmacologia , Ratos , Ratos Sprague-Dawley , Receptor CB2 de Canabinoide/antagonistas & inibidores , Receptor CB2 de Canabinoide/fisiologia , Rimonabanto , Tiazóis/farmacologiaRESUMO
BACKGROUND AND PURPOSE: Activation of cannabinoid CB1 and/or CB2 receptors mediates analgesic effects across a broad spectrum of preclinical pain models. Selective activation of CB2 receptors may produce analgesia without the undesirable psychotropic side effects associated with modulation of CB1 receptors. To address selectivity in vivo, we describe non-invasive, non-ionizing, functional data that distinguish CB1 from CB2 receptor neural activity using pharmacological MRI (phMRI) in awake rats. EXPERIMENTAL APPROACH: Using a high field (7 T) MRI scanner, we examined and quantified the effects of non-selective CB1/CB2 (A-834735) and selective CB2 (AM1241) agonists on neural activity in awake rats. Pharmacological specificity was determined using selective CB1 (rimonabant) or CB2 (AM630) antagonists. Behavioural studies, plasma and brain exposures were used as benchmarks for activity in vivo. KEY RESULTS: The non-selective CB1/CB2 agonist produced a dose-related, region-specific activation of brain structures that agrees well with published autoradiographic CB1 receptor density binding maps. Pretreatment with a CB1 antagonist but not with a CB2 antagonist, abolished these activation patterns, suggesting an effect mediated by CB1 receptors alone. In contrast, no significant changes in brain activity were found with relevant doses of the CB2 selective agonist. CONCLUSION AND IMPLICATIONS: These results provide the first clear evidence for quantifying in vivo functional selectivity between CB1 and CB2 receptors using phMRI. Further, as the presence of CB2 receptors in the brain remains controversial, our data suggest that if CB2 receptors are expressed, they are not functional under normal physiological conditions.
Assuntos
Encéfalo/efeitos dos fármacos , Agonistas de Receptores de Canabinoides , Algoritmos , Animais , Comportamento Animal/efeitos dos fármacos , Células Cultivadas , Circulação Cerebrovascular/efeitos dos fármacos , Humanos , Interpretação de Imagem Assistida por Computador , Inflamação/complicações , Imageamento por Ressonância Magnética , Masculino , Atividade Motora/efeitos dos fármacos , Dor/tratamento farmacológico , Dor/etiologia , Doenças do Sistema Nervoso Periférico/complicações , Equilíbrio Postural/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Receptor CB1 de Canabinoide/agonistas , Receptor CB1 de Canabinoide/antagonistas & inibidores , Receptor CB2 de Canabinoide/agonistas , Receptor CB2 de Canabinoide/antagonistas & inibidoresRESUMO
BACKGROUND AND PURPOSE: Selective cannabinoid CB2 receptor agonists have demonstrated analgesic activity across multiple preclinical pain models. AM1241 is an indole derivative that exhibits high affinity and selectivity for the CB2 binding site and broad spectrum analgesic activity in rodent models, but is not an antagonist of CB2 in vitro functional assays. Additionally, its analgesic effects are mu-opioid receptor-dependent. Herein, we describe the in vitro and in vivo pharmacological properties of A-796260, a novel CB2 agonist. EXPERIMENTAL APPROACH: A-796260 was characterized in radioligand binding and in vitro functional assays at rat and human CB1 and CB2 receptors. The behavioural profile of A-796260 was assessed in models of inflammatory, post-operative, neuropathic, and osteoarthritic (OA) pain, as well as its effects on motor activity. The receptor specificity was confirmed using selective CB1, CB2 and mu-opioid receptor antagonists. KEY RESULTS: A-796260 exhibited high affinity and agonist efficacy at human and rat CB2 receptors, and was selective for the CB2 vs CB1 subtype. Efficacy in models of inflammatory, post-operative, neuropathic and OA pain was demonstrated, and these activities were selectively blocked by CB2, but not CB1 or mu-opioid receptor-selective antagonists. Efficacy was achieved at doses that had no significant effects on motor activity. CONCLUSIONS AND IMPLICATIONS: These results further confirm the therapeutic potential of CB2 receptor-selective agonists for the treatment of pain. In addition, they demonstrate that A-796260 may be a useful new pharmacological compound for further studying CB2 receptor pharmacology and for evaluating its role in the modulation of pain.
Assuntos
Analgésicos não Narcóticos/farmacologia , Ciclopropanos/farmacologia , Morfolinas/farmacologia , Dor/tratamento farmacológico , Receptor CB2 de Canabinoide/agonistas , Analgésicos não Narcóticos/uso terapêutico , Animais , Artrite Experimental/tratamento farmacológico , Artrite Experimental/patologia , Células Cultivadas , Constrição Patológica/complicações , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Cicloexanóis/farmacologia , Ciclopropanos/uso terapêutico , Humanos , Hiperalgesia/tratamento farmacológico , Hiperalgesia/patologia , Imunossupressores/farmacologia , Articulações/patologia , Masculino , Microscopia de Fluorescência , Morfolinas/uso terapêutico , Atividade Motora/efeitos dos fármacos , Ensaio Radioligante , Ratos , Ratos Sprague-Dawley , Ciática/tratamento farmacológico , Ciática/etiologiaRESUMO
BACKGROUND AND PURPOSE: The CB2 receptor has been proposed as a novel target for the treatment of pain, and CB2 receptor agonists defined in in vitro assays have demonstrated analgesic activity in animal models. Based on its in vivo analgesic efficacy, AM1241 has been classified as a CB2-selective agonist. However, in vitro characterization of AM1241 in functional assays has not been reported. EXPERIMENTAL APPROACH: In this study, AM1241 was characterized across multiple in vitro assays employing heterologous recombinant receptor expression systems to assess its binding potencies at the human CB2 and CB1 receptors and its functional efficacies at the human CB2 receptor. KEY RESULTS: AM1241 exhibited distinct functional properties depending on the assay conditions employed, a unique profile in contrast to those of the agonist CP 55,940 and the inverse agonist SR144528. AM1241 displayed neutral antagonist activities in FLIPR and cyclase assays. However, when cyclase assays were performed using lower forskolin concentrations for stimulation, AM1241 exhibited partial agonist efficacy. In addition, it behaved as a partial agonist in ERK (or MAP) kinase assays. CONCLUSIONS AND IMPLICATIONS: The unusual phenomenon of inconsistent functional efficacies suggests that AM1241 is a protean agonist at the CB2 receptor. We postulate that functional efficacies displayed by protean agonists in various assay systems may depend on the levels of receptor constitutive activities exhibited in the assay systems, and therefore, efficacies observed in in vitro assays may not predict in vivo activities.
Assuntos
Receptor CB2 de Canabinoide/agonistas , Canabinoides/farmacologia , Linhagem Celular , HumanosRESUMO
Objectifs Analyser les donnees epidemiologiques; diagnostiques et therapeutiques des complications uro-genitales de 41 cas de traumatismes du bassin. Patients et methode Il s'agit d'une etude retrospective effectuee a partir de 41 cas de traumatismes du bassin avec complication urinaire et/ou genitale colliges dans le service d'urologie du CHU de Treichville sur une periode de cinq ans. L'age moyen des patients est de 27;8 ans (extremes: 14 a 48 ans); avec un sexe ratio de 9;25 hommes pour une femme. Resultats Les accidents de la voie publique sont les plus grands pourvoyeurs de traumatisme representant 75;6des cas. Les fractures de l'arc anterieur sont les plus incriminees (26;9). Les signes cliniques les plus evocateurs sont : la retention aigue d'urines (16;7); l'uretrorragie (10;4) et l'hematurie (29;1). Nous avons observe 50de lesions uretrales; 38;5de lesions vesicales; 9;6d'atteintes des organes genitaux externes et 1;9de lesions prostatiques. Nous avons opte pour une reparation a distance du traumatisme causal (3 mois) pour les ruptures de l'uretre membraneux en faisant une large part a la resection-anastomose avec spatulation (51;16). Nous avons obtenu 66de bons resultats sur le plan urinaire et 73de conservation d'une fonction erectile satisfaisante tandis qu'une mortalite de 4;9assombrit le pronostic. Conclusion Le pronostic peut etre ameliore par la celerite du diagnostic et la prise en charge des lesions qui sont squelettiques et souvent poly-viscerales chez les patients presentant des lesions uro-genitales consecutifs aux traumatismes du bassin; c'est a dire la necessite d'une prise en charge specialisee pluridisciplinaire
Assuntos
Côte d'Ivoire , Doenças Urogenitais Femininas , Pacientes , Dor Pélvica , Ferimentos e Lesões/complicaçõesAssuntos
Benzofuranos/farmacologia , Cognição/efeitos dos fármacos , Antagonistas dos Receptores Histamínicos/farmacologia , Pirrolidinas/farmacologia , Receptores Histamínicos H3/metabolismo , Esquizofrenia/tratamento farmacológico , Esquizofrenia/metabolismo , Animais , Benzofuranos/uso terapêutico , Cognição/fisiologia , Antagonistas dos Receptores Histamínicos/uso terapêutico , Memória/efeitos dos fármacos , Memória/fisiologia , Camundongos , Camundongos Endogâmicos DBA , Modelos Animais , Pirrolidinas/uso terapêutico , Ratos , Ratos WistarAssuntos
Compostos de Bifenilo/farmacologia , Agonistas dos Receptores Histamínicos/farmacologia , Piperazinas/farmacologia , Receptores Histamínicos H3/metabolismo , Animais , Compostos de Bifenilo/química , Linhagem Celular , Agonistas dos Receptores Histamínicos/química , Humanos , Imidazóis/química , Estrutura Molecular , Piperazinas/química , Ensaio Radioligante , RatosAssuntos
Antagonistas dos Receptores Histamínicos/farmacologia , Obesidade/tratamento farmacológico , Receptores Histamínicos H3/metabolismo , Animais , Membrana Celular/metabolismo , Córtex Cerebelar/metabolismo , Antagonistas dos Receptores Histamínicos/química , Humanos , Ratos , Relação Estrutura-AtividadeAssuntos
Antagonistas dos Receptores Histamínicos/farmacologia , Piperazinas/farmacologia , Receptores Histamínicos H3/efeitos dos fármacos , 1-Metil-3-Isobutilxantina/farmacologia , Ligação Competitiva/efeitos dos fármacos , Colforsina/farmacologia , AMP Cíclico/metabolismo , Agonistas dos Receptores Histamínicos/metabolismo , Humanos , Ligantes , Metilistaminas/metabolismo , Inibidores de Fosfodiesterase/farmacologia , Receptores Histamínicos H3/metabolismoAssuntos
Antagonistas dos Receptores Histamínicos/síntese química , Antagonistas dos Receptores Histamínicos/farmacologia , Piperazinas/síntese química , Piperazinas/farmacologia , Receptores Histamínicos H3/efeitos dos fármacos , Alanina/química , Amidas/química , Animais , Ligação Competitiva/efeitos dos fármacos , Humanos , Indicadores e Reagentes , Cinética , Ratos , Proteínas Recombinantes/metabolismoRESUMO
Presynaptic histamine H(3) receptors (H(3)R) regulate neurotransmitter release in the central nervous system, suggesting an important role for H(3) ligands in human diseases such as cognitive disorders, sleep disturbances, epilepsy, or obesity. Drug development for many of these human diseases relies upon rodent-based models. Although there is significant sequence homology between the human and rat H(3)Rs, some compounds show distinct affinity profiles. To identify the amino acids responsible for these species disparities, various mutant receptors were generated and their pharmacology studied. The N-terminal portion was shown to determine the species differences in ligand binding since a chimeric H(3)R containing N-terminal human and C-terminal rat receptor sequences exhibited similar pharmacology to the human receptor. Sequence analysis and molecular modeling studies suggested key amino acids at positions 119 and 122 in transmembrane region 3 play important roles in ligand recognition. Mutant receptors changing amino acids 119 or 122 of the human receptor to those in the rat improved ligand binding affinities and functional potencies of antagonist ligands, confirming the significant role that these amino acids play in species-related pharmacological differences. A model has been developed to elucidate the ligand receptor interactions for H(3)Rs, and pharmacological aspects of this model are described.
Assuntos
Antagonistas dos Receptores Histamínicos/farmacologia , Receptores Histamínicos H3/efeitos dos fármacos , Receptores Histamínicos H3/genética , Sequência de Aminoácidos , Animais , Ligação Competitiva , Linhagem Celular , Córtex Cerebral/metabolismo , Clonagem Molecular , Humanos , Modelos Moleculares , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Ensaio Radioligante , Ratos , Receptores Histamínicos H3/fisiologia , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Alinhamento de Sequência , Especificidade da EspécieRESUMO
Signal transduction by interleukin-12 (IL-12) requires phosphorylation and activation of STAT4. Direct interaction of the SH2 domain of STAT4 with a phosphotyrosine residue in the IL-12 receptor has been proposed to be required for the subsequent STAT4 phosphorylation. The IL-12 receptor beta2 subunit contains three tyrosine residues in its cytoplasmic domain. To test the hypothesis that one of these tyrosines is involved in binding STAT4, phosphopeptides were synthesized according to the amino acid sequences surrounding each of these tyrosine residues. Only the phosphopeptide containing pTyr800 strongly bound to STAT4 in a cell-free binding assay. When this phosphopeptide was introduced into TALL-104 cells, it blocked IL-12-induced STAT4 phosphorylation by competing with the IL-12 receptor for binding to STAT4. A series of alanine replacements was performed in this phosphopeptide to elucidate which amino acids surrounding the pTyr800 residue are critical for STAT4 binding. To summarize, the site on the IL-12 receptor which binds STAT4 can be described as -T-X-X-G-pY(800)-L-, where the core G-pY(800)-L motif is critical for the binding; the threonine at the pY-4 position has only a minor contribution and X represents amino acids not critical for the binding. These results demonstrate that only a small region of the IL-12 receptor is critically involved in binding STAT4 and suggest the feasibility that small molecule inhibitors could be identified which interfere with IL-12 signal transduction for treatment of autoimmune diseases.